RxDoctor Payments Data

Andrew Axelrad, MD

Gastroenterology · Reston, VANPI 1073579876

Payments from drug & device makers

$8,886in general payments, 2019–2025

Across 433 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$2K
  • Pfizer$769
  • Gilead$639
  • Takeda Pharmaceuticals U.S.A., Inc.$497
  • Johnson & Johnson$426
  • plus $2K from 25 others

What the payments were for

  • Consulting fees$160%
  • Food & beverage$8,77999%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,886 in reported general payments places this provider in the 70th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$485,004
Medicare patients
618
Services billed
15,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab25$580,532
CreonLipase/Protease/Amylase18$68,798
LinzessLinaclotide23$15,675
Dexlansoprazole DrDexlansoprazole20$6,839
Mesalamine14$5,693
Ursodiol17$3,896
Rabeprazole Sodium35$1,393
CholestyramineCholestyramine (With Sugar)18$978
Pantoprazole Sodium29$432
Esomeprazole Magnesium15$329
Omeprazole18$243
Azathioprine14$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$426$580,53225 claims
AbbVieCreon, Linzess$2,466$84,47341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Reston

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →